Shopping Cart 0
Cart Subtotal
USD 0

GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK's vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc (GSK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 11

List of Figures 16

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 18

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 20

GlaxoSmithKline Plc, Medical Devices Deals, 2012 to YTD 2018 22

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 23

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deal Details 46

Asset Purchase 46

ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 46

ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 48

GlaxoSmithKline Acquires Consumer Healthcare Pharma Business of Novartis 49

GlaxoSmithKline Acquires Vaccines Business of Novartis for up to USD7.1 Billion 51

Novartis India to Sell Its OTC Division to GlaxoSmithKline Consumer 53

ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 54

Stiefel Labs Acquires WBI-1001 From Welichem Biotech For USD 34 Million 55

Venture Financing 57

Gotham Therapeutics Raises USD54 Million in Series A Financing 57

Sitryx Therapeutics Raises USD30 Million in Series A Financing 59

Morphic Therapeutic Raises USD80 Million in Series B Financing 61

Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 63

Nimbus Therapeutics Raises USD65 Million in Financing 65

Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 67

Constellation Pharma Raises USD100 Million in Financing 69

Macrolide Pharma Raises USD20 Million in Venture Financing 71

Pandion Therapeutics Raises USD58 Million in Series A Finanicng 72

Atox Bio Raises USD30 Million in Financing 73

Palleon Pharma Raises USD47.6 Million in Series A Financing 75

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 76

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 78

TP Therapeutics Raises USD45 Million in Series C Financing 80

Pulmocide Raises USD30.4 Million in Series B Financing 81

Spero Therapeutics Raises USD51.7 Million in Series C Financing 83

Tioma Therapeutics Raises USD86 Million in Series A Financing 85

Second Genome Raises USD8.4 Million in Extended Series B Financing 86

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 87

PDI Therapeutics to Raise up to USD10 Million in Series A Venture Financing 89

Spero Therapeutics Raises USD30 Million in Series B Funding 90

Mission Therapeutics Raises USD85.7 Million in Financing Round 92

Nkarta Raises Funds through Venture Financing 94

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 95

Navitor Pharma Raises USD33 Million in Series B Financing 97

Constellation Pharma Raises USD55 Million Financing 99

True North Therapeutics Raises USD40 Million in Series C Financing 101

Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 103

Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 104

Atreca Raises USD56 Million in Series A Financing 105

Puridify Raises USD3.4 Million in Series A Financing 107

Decibel Therapeutics Raises USD52 Million in Series A Financing Round 108

Asceneuron Raises USD30.6 Million in Series A Financing 109

Gladius Pharma Raises USD3.3 Million in Series A Financing 111

Atopix Therapeutics Raises Additional Funds through Venture Financing 112

Adrenergics Raises up to USD10 Million in Series A Financing 113

CadheRx Therapeutics Raises up to USD10 Million in Series A Financing 114

Calporta Therapeutics Raises up to USD10 Million in Series A Financing 115

Spero Therapeutics Raises USD30 Million in Extended Series A Financing 116

PsiOxus Therapeutics Raises USD39.2 Million in Series C Financing 118

CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 120

CRISPR Therapeutics Raises USD29 Million in Series B Financing 122

ZappRx Raises USD5.6 Million in Series A Financing 124

Thrasos Therapeutics Raises USD21 Million in Series D Financing 125

Nimbus Therapeutics Raises USD43 Million in Series B Financing 127

Macrolide Pharma Raises USD22 Million in Series A Financing 129

Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 130

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 132

Atopix Therapeutics Raises Funds through Extended Series A Financing 134

Silarus Therapeutics to Raise up to USD10 Million in Series A Venture Financing 135

Thyritope Biosciences to Raise up to USD10 Million in Series A Venture Financing 136

Atox Bio Raises up to USD23 Million in Series E Venture Financing 137

Navitor Pharma Raises USD24 Million in Series A Financing 138

True North Therapeutics Raises USD22 Million in Series A Venture Financing 140

Puridify Raises USD1.43 Million in Seed Funding 142

Principia Biopharma Raises USD 50 Million In Series B Venture Financing 143

Spero Therapeutics Raises USD3 Million in Series A Venture Financing 145

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 146

RuiYi Raises USD 15 Million In Series B Financing 147

HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 149

VHsquared Secures Series A Funding Round 150

Sitari Pharma Raises USD 10 Million In Series A Financing 151

Mission Therapeutics Raises USD 32 Million In Series B Financing 152

Aileron Therapeutics Raises USD 30 Million In Series E Financing 154

F-Star Alpha Raises USD 13 Million In Series A Financing 156

iPierian Raises USD 30 Million In Series A Venture Financing 158

Effector Therapeutics Raises USD 45 Million In Series A Financing 160

Progenitor Labs Raises USD 5.8 Million In Seed Financing 162

Aileron Raises USD 12 Million In Extended Series D Financing 163

NeRRe Therapeutics Raises USD 18 Million In Series A Financing 165

River Vision Development Raises USD 17 Million In Series A Financing 166

Bicycle Therapeutics Raises USD 6 Million In Venture Financing 167

Applied Genetic Technologies Raises USD 37.5 Million In Series B Financing 169

HTG Molecular Diagnostics Raises USD 7.5 Million In Series E Financing 171

Thrasos Therapeutics Raises USD 35 Million In Venture Financing 172

SR One Plans To Invest In Biotechnology Company 174

Genocea Biosciences Raises USD 30 Million In Series C Financing 175

Principia Biopharma Raises Additional USD 13 Million In Series A Financing 177

PsiOxus Therapeutics Raises Additional USD 34 Million In Series B Financing 179

RaNA Therapeutics Raises Additional USD 18 Million In Series A Financing 181

Partnerships 183

GlaxoSmithKline and 23andMe Enter into Collaboration Agreement 183

MolMed Enters into Development Agreement with GlaxoSmithKline 185

Cloud Pharma Enters into Partnership with GlaxoSmithKline 186

Kymera Therapeutics Enters into Agreement with GlaxoSmithKline 187

National Institute for Health Research Enters into Research Agreement with GlaxoSmithKline 188

Owlstone Medical Enters into Co-Development Agreement with GlaxoSmithKline 189

Plasticell Enters into Agreement with GlaxoSmithKline 190

AbCellera Biologics Enters into Research Partnership with GlaxosmithKline 191

Oklahoma Medical Research Foundation Enters into Agreement with GlaxoSmithKline 192

Exscientia Enters into Partnership with GlaxoSmithKline (GSK) 193

Aseptic Technologies Enters into Agreement with MedCision 194

Warp Drive Bio Enters to Agreement with GlaxoSmithKline 195

Telo Therapeutics Enters into Research Agreement with GlaxoSmithKline 196

GlaxoSmithKline Biologicals Enters into Option Agreement with Aridis Pharma 197

Puridify Enters into Agreement with GlaxoSmithKline 198

Fimbrion Therapeutics Enters into Co-Development Agreement with GlaxoSmithKline 199

GlaxoSmithKline Enters into Co-Development Agreement with University of Leicester 200

GlaxoSmithKline Forms Joint Venture with Avalon Ventures 201

GlaxoSmithKline Enters into Agreement with Miltenyi Biotec 202

VBI Vaccines Enters into Research Agreement with GlaxoSmithKline Biologicals 203

Valneva Enters into R&D Agreement with GlaxoSmithKline 204

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 205

GlaxoSmithKline Enters into Research Agreement with NIAID 206

GlaxoSmithKline Forms Iron Horse Therapeutics with Avalon Ventures 207

GlaxoSmithKline Partners with Merck 208

Pfizer Enters into Agreement with GlaxoSmithKline 209

UC San Francisco Enters into Research Agreement with GlaxoSmithKline 210

MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 211

GlaxoSmithKline Enters into Partnership with Francis Crick Institute 212

University of North Carolina Forms Joint Venture with GlaxoSmithKline 213

Cold Spring Harbor Labs Enters into Co-Development Agreement with GlaxoSmithKline 214

MolMed Enters into Agreement with GlaxoSmithKline 215

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 216

GlaxoSmithKline, Monash University, McCall MacBain Foundation, Grand Challenges Canada and Planet Wheeler Foundation Enter into Co-Development Agreement 218

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 219

Bioversys Enters into Agreement with GlaxoSmithKline and University of Lille 220

Metabolon Enters Into Agreement With GlaxoSmithKline For Metabolomic Profiling Services 221

GlaxoSmithKline Enters Into Agreement With University of Texas MD Anderson Cancer Center For Immunotherapy Drugs 222

BioRap Enters into Agreement with GlaxoSmithKline 223

GlaxoSmithKline Enters into Partnership with Yale University 224

Santaris Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For RNA-Targeted Medicines 225

GlaxoSmithKline Forms Joint Venture With Biological E 226

ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 227

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 228

GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 229

GlaxoSmithKline Expands its Partnership with Adimab 230

GlaxoSmithKline Plans To Partner With Chinese Companies 231

GlaxoSmithKline Enters Into Co-Development Agreement With Institute of Chemical Engineering And Sciences 232

Eddingpharm Enters Into Distribution Agreement With GlaxoSmithKline For Tykerb 233

AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 234

Proteologics And GlaxoSmithKline Extend Their Research Agreement 235

Hospital for Sick Children Enters Into Research Agreement With GlaxoSmithKline To Discover Treatment For Cystic Fibrosis 236

Vanderbilt University Enters Into Research Agreement With GlaxoSmithKline For Obesity Drug 237

Priaxon Enters Into Co-Development Agreement With GlaxoSmithKline For Small Molecule Modulators Of PPIs 238

Chroma Therapeutics Expands Co-Development Agreement With GlaxoSmithKline 239

GlycoVaxyn Enters Into Co-Development Agreement With GlaxoSmithKline For Bacterial Vaccines 240

Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 241

GlaxoSmithKline Enters Into Agreement With Imagine Institute To Discover New Drugs For Netherton Syndrome 242

Chiromics Enters Into Drug Discovery Agreement With GlaxoSmithKline 243

Aeras Enters Into R&D Agreement With GlaxoSmithKline Vaccines To Develop Tuberculosis Vaccine 244

GlaxoSmithKline Enters Into Co-Development Agreement With University of Cambridge 245

PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 246

Daiichi Sankyo And GlaxoSmithKline Form Joint Venture In Japan 247

Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 248

Desitin Arzneimittel Enters Into Co-Promotion Agreement With GlaxoSmithKline For Elontril 249

GlaxoSmithKline Enters Into Co-Development Agreement With Yale University 250

Five Prime Therapeutics Amends Agreement With GlaxoSmithKline 251

Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 252

GlaxoSmithKline Enters Into Co-Development Agreement With University of Dundee 253

Angiochem Enters Into Co-Development Agreement With GlaxoSmithKline 254

GlaxoSmithKline Enters Into Agreement With Coland Holdings 255

GlaxoSmithKline Enters Into Co-Development Agreement With Sienna Biotec 256

Eddingpharm Enters Distribution Agreement With GlaxoSmithKline For Relafen 257

Licensing Agreements 258

Boston Pharma Enters into Licensing Agreement with GlaxoSmithKline 258

GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 259

Zai Lab Enters into Licensing agreement with GlaxoSmithKline 260

GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 261

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 262

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 263

Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 264

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 265

GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 266

Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 267

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 268

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 269

Codexis Enters into Licensing Agreement with GlaxoSmithKline for CodeEvolver Protein Engineering Platform 270

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 272

GlaxoSmithKline Enters into Licensing Agreement with Adaptimmune Therapeutics 273

GlaxoSmithKline Exercises Licensing Agreement with Adaptimmune 274

GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 276

GlaxoSmithKline Enters Into Licensing Agreement With Adimab 277

Immunocore Enters Into Licensing Agreement With GSK For ImmTACs 278

MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 279

GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 281

GlaxoSmithKline Enters Into Licensing Agreement With University of Texas MD Anderson Cancer Center For Antibodies 282

NeRRe Therapeutics Receives Neurokinin Receptor Antagonists from GlaxoSmithKline 283

Basilea Pharmaceutical Amends Terms of Licensing Agreement with Stiefel Labs for Toctino 284

Liquidia Technologies Exercises Option for Licensing Agreement with GlaxoSmithKline 286

GlaxoSmithKline Enters into Licensing Agreement with Pelago Bioscience for CETSA 287

Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 288

Medicines Patent Pool Extends Licensing Agreement with ViiV Healthcare 289

ViiV Healthcare Enters Into Licensing Agreement With Medicines Patent Pool For Epzicom 290

GlaxoSmithKline Enters Into Licensing Agreement With Alacris Theranostics For ModCell System 291

ViiV Healthcare Announces Licensing Agreement For Celsentri 292

GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 293

Equity Offering 294

Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 294

Theravance Biopharma Raises USD23 Million in Private Placement of Shares 296

Amicus Therapeutics Completes Private Placement Of Securities For USD 15 Million 297

GlaxoSmithKline Plc - Key Competitors 394

GlaxoSmithKline Plc - Key Employees 395

GlaxoSmithKline Plc - Locations And Subsidiaries 396

Head Office 396

Other Locations & Subsidiaries 396

Joint Venture 409

Recent Developments 410

Financial Announcements 410

Jul 25, 2018: GSK delivers improvements in sales, margins and cash flow in Q2 2018 410

Feb 07, 2018: GSK delivers improvements in sales, margins and cash flow in 2017 413

Oct 25, 2017: GSK delivers Q3 sales of 7.8 billion, +4% AER, +2% CER 414

Jul 26, 2017: GSK delivers further progress in Q2 and sets out new priorities for the Group 426

Apr 26, 2017: GSK delivers another quarter of continued progress 432

Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 435

Corporate Communications 451

Aug 07, 2018: Iain Mackay appointed GSK Chief Financial Officer 451

Jun 12, 2018: GSK announces changes to Vaccines and Global Manufacturing & Supply leadership 452

May 09, 2018: Simon Dingemans, Chief Financial Officer, to retire from GSK 453

Apr 18, 2018: GlaxoSmithKline Names Kevin Sin as new Senior Vice President and Head of Worldwide Business Development for Research & Development 454

Jan 09, 2018: Representative Director and President of GlaxoSmithKline Corporation Personnel notice 455

Nov 08, 2017: Patrick Vallance, President, R&D, GSK to become UK Government's Chief Scientific Adviser 456

Nov 08, 2017: Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK 457

Jul 25, 2017: Karenann Terrell appointed Chief Digital & Technology Officer, GSK 458

Jul 21, 2017: GSK announces Board and Committee changes 459

Jun 19, 2017: GSK confirms start date for Luke Miels 460

Jun 05, 2017: Four innovations to tackle under-five deaths win USD 1 million Healthcare Innovation Award from GSK and Save the Children 461

Apr 04, 2017: GSK responds to Cyclone Debbie 463

Jan 20, 2017: Luke Miels will succeed Abbas Hussain as President, Global Pharmaceuticals, GSK 464

Jan 19, 2017: Abbas Hussain to leave GSK 465

Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 466

Legal and Regulatory 467

Appendix 514

Methodology 514

About GlobalData 514

Contact Us 514

Disclaimer 514


List Of Figure

List of Figures

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 18

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 20

GlaxoSmithKline Plc, Medical Devices Deals, 2012 to YTD 2018 22


List Of Table

List of Tables

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 18

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19

GlaxoSmithKline Plc, Deals By Therapy Area, 2012 to YTD 2018 20

GlaxoSmithKline Plc, Medical Devices Deals, 2012 to YTD 2018 22

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 23

ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 46

ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 48

GlaxoSmithKline Acquires Consumer Healthcare Pharma Business of Novartis 49

GlaxoSmithKline Acquires Vaccines Business of Novartis for up to USD7.1 Billion 51

Novartis India to Sell Its OTC Division to GlaxoSmithKline Consumer 53

ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 54

Stiefel Labs Acquires WBI-1001 From Welichem Biotech For USD 34 Million 55

Gotham Therapeutics Raises USD54 Million in Series A Financing 57

Sitryx Therapeutics Raises USD30 Million in Series A Financing 59

Morphic Therapeutic Raises USD80 Million in Series B Financing 61

Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 63

Nimbus Therapeutics Raises USD65 Million in Financing 65

Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 67

Constellation Pharma Raises USD100 Million in Financing 69

Macrolide Pharma Raises USD20 Million in Venture Financing 71

Pandion Therapeutics Raises USD58 Million in Series A Finanicng 72

Atox Bio Raises USD30 Million in Financing 73

Palleon Pharma Raises USD47.6 Million in Series A Financing 75

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 76

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 78

TP Therapeutics Raises USD45 Million in Series C Financing 80

Pulmocide Raises USD30.4 Million in Series B Financing 81

Spero Therapeutics Raises USD51.7 Million in Series C Financing 83

Tioma Therapeutics Raises USD86 Million in Series A Financing 85

Second Genome Raises USD8.4 Million in Extended Series B Financing 86

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 87

PDI Therapeutics to Raise up to USD10 Million in Series A Venture Financing 89

Spero Therapeutics Raises USD30 Million in Series B Funding 90

Mission Therapeutics Raises USD85.7 Million in Financing Round 92

Nkarta Raises Funds through Venture Financing 94

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 95

Navitor Pharma Raises USD33 Million in Series B Financing 97

Constellation Pharma Raises USD55 Million Financing 99

True North Therapeutics Raises USD40 Million in Series C Financing 101

Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 103

Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 104

Atreca Raises USD56 Million in Series A Financing 105

Puridify Raises USD3.4 Million in Series A Financing 107

Decibel Therapeutics Raises USD52 Million in Series A Financing Round 108

Asceneuron Raises USD30.6 Million in Series A Financing 109

Gladius Pharma Raises USD3.3 Million in Series A Financing 111

Atopix Therapeutics Raises Additional Funds through Venture Financing 112

Adrenergics Raises up to USD10 Million in Series A Financing 113

CadheRx Therapeutics Raises up to USD10 Million in Series A Financing 114

Calporta Therapeutics Raises up to USD10 Million in Series A Financing 115

Spero Therapeutics Raises USD30 Million in Extended Series A Financing 116

PsiOxus Therapeutics Raises USD39.2 Million in Series C Financing 118

CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 120

CRISPR Therapeutics Raises USD29 Million in Series B Financing 122

ZappRx Raises USD5.6 Million in Series A Financing 124

Thrasos Therapeutics Raises USD21 Million in Series D Financing 125

Nimbus Therapeutics Raises USD43 Million in Series B Financing 127

Macrolide Pharma Raises USD22 Million in Series A Financing 129

Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 130

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 132

Atopix Therapeutics Raises Funds through Extended Series A Financing 134

Silarus Therapeutics to Raise up to USD10 Million in Series A Venture Financing 135

Thyritope Biosciences to Raise up to USD10 Million in Series A Venture Financing 136

Atox Bio Raises up to USD23 Million in Series E Venture Financing 137

Navitor Pharma Raises USD24 Million in Series A Financing 138

True North Therapeutics Raises USD22 Million in Series A Venture Financing 140

Puridify Raises USD1.43 Million in Seed Funding 142

Principia Biopharma Raises USD 50 Million In Series B Venture Financing 143

Spero Therapeutics Raises USD3 Million in Series A Venture Financing 145

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 146

RuiYi Raises USD 15 Million In Series B Financing 147

HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 149

VHsquared Secures Series A Funding Round 150

Sitari Pharma Raises USD 10 Million In Series A Financing 151

Mission Therapeutics Raises USD 32 Million In Series B Financing 152

Aileron Therapeutics Raises USD 30 Million In Series E Financing 154

F-Star Alpha Raises USD 13 Million In Series A Financing 156

iPierian Raises USD 30 Million In Series A Venture Financing 158

Effector Therapeutics Raises USD 45 Million In Series A Financing 160

Progenitor Labs Raises USD 5.8 Million In Seed Financing 162

Aileron Raises USD 12 Million In Extended Series D Financing 163

NeRRe Therapeutics Raises USD 18 Million In Series A Financing 165

River Vision Development Raises USD 17 Million In Series A Financing 166

Bicycle Therapeutics Raises USD 6 Million In Venture Financing 167

Applied Genetic Technologies Raises USD 37.5 Million In Series B Financing 169

HTG Molecular Diagnostics Raises USD 7.5 Million In Series E Financing 171

Thrasos Therapeutics Raises USD 35 Million In Venture Financing 172

SR One Plans To Invest In Biotechnology Company 174

Genocea Biosciences Raises USD 30 Million In Series C Financing 175

Principia Biopharma Raises Additional USD 13 Million In Series A Financing 177

PsiOxus Therapeutics Raises Additional USD 34 Million In Series B Financing 179

RaNA Therapeutics Raises Additional USD 18 Million In Series A Financing 181

GlaxoSmithKline and 23andMe Enter into Collaboration Agreement 183

MolMed Enters into Development Agreement with GlaxoSmithKline 185

Cloud Pharma Enters into Partnership with GlaxoSmithKline 186

Kymera Therapeutics Enters into Agreement with GlaxoSmithKline 187

National Institute for Health Research Enters into Research Agreement with GlaxoSmithKline 188

Owlstone Medical Enters into Co-Development Agreement with GlaxoSmithKline 189

Plasticell Enters into Agreement with GlaxoSmithKline 190

AbCellera Biologics Enters into Research Partnership with GlaxosmithKline 191

Oklahoma Medical Research Foundation Enters into Agreement with GlaxoSmithKline 192

Exscientia Enters into Partnership with GlaxoSmithKline (GSK) 193

Aseptic Technologies Enters into Agreement with MedCision 194

Warp Drive Bio Enters to Agreement with GlaxoSmithKline 195

Telo Therapeutics Enters into Research Agreement with GlaxoSmithKline 196

GlaxoSmithKline Biologicals Enters into Option Agreement with Aridis Pharma 197

Puridify Enters into Agreement with GlaxoSmithKline 198

Fimbrion Therapeutics Enters into Co-Development Agreement with GlaxoSmithKline 199

GlaxoSmithKline Enters into Co-Development Agreement with University of Leicester 200

GlaxoSmithKline Forms Joint Venture with Avalon Ventures 201

GlaxoSmithKline Enters into Agreement with Miltenyi Biotec 202

VBI Vaccines Enters into Research Agreement with GlaxoSmithKline Biologicals 203

Valneva Enters into R&D Agreement with GlaxoSmithKline 204

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 205

GlaxoSmithKline Enters into Research Agreement with NIAID 206

GlaxoSmithKline Forms Iron Horse Therapeutics with Avalon Ventures 207

GlaxoSmithKline Partners with Merck 208

Pfizer Enters into Agreement with GlaxoSmithKline 209

UC San Francisco Enters into Research Agreement with GlaxoSmithKline 210

MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 211

GlaxoSmithKline Enters into Partnership with Francis Crick Institute 212

University of North Carolina Forms Joint Venture with GlaxoSmithKline 213

Cold Spring Harbor Labs Enters into Co-Development Agreement with GlaxoSmithKline 214

MolMed Enters into Agreement with GlaxoSmithKline 215

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 216

GlaxoSmithKline, Monash University, McCall MacBain Foundation, Grand Challenges Canada and Planet Wheeler Foundation Enter into Co-Development Agreement 218

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 219

Bioversys Enters into Agreement with GlaxoSmithKline and University of Lille 220

Metabolon Enters Into Agreement With GlaxoSmithKline For Metabolomic Profiling Services 221

GlaxoSmithKline Enters Into Agreement With University of Texas MD Anderson Cancer Center For Immunotherapy Drugs 222

BioRap Enters into Agreement with GlaxoSmithKline 223

GlaxoSmithKline Enters into Partnership with Yale University 224

Santaris Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For RNA-Targeted Medicines 225

GlaxoSmithKline Forms Joint Venture With Biological E 226

ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 227

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 228

GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 229

GlaxoSmithKline Expands its Partnership with Adimab 230

GlaxoSmithKline Plans To Partner With Chinese Companies 231

GlaxoSmithKline Enters Into Co-Development Agreement With Institute of Chemical Engineering And Sciences 232

Eddingpharm Enters Into Distribution Agreement With GlaxoSmithKline For Tykerb 233

AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 234

Proteologics And GlaxoSmithKline Extend Their Research Agreement 235

Hospital for Sick Children Enters Into Research Agreement With GlaxoSmithKline To Discover Treatment For Cystic Fibrosis 236

Vanderbilt University Enters Into Research Agreement With GlaxoSmithKline For Obesity Drug 237

Priaxon Enters Into Co-Development Agreement With GlaxoSmithKline For Small Molecule Modulators Of PPIs 238

Chroma Therapeutics Expands Co-Development Agreement With GlaxoSmithKline 239

GlycoVaxyn Enters Into Co-Development Agreement With GlaxoSmithKline For Bacterial Vaccines 240

Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 241

GlaxoSmithKline Enters Into Agreement With Imagine Institute To Discover New Drugs For Netherton Syndrome 242

Chiromics Enters Into Drug Discovery Agreement With GlaxoSmithKline 243

Aeras Enters Into R&D Agreement With GlaxoSmithKline Vaccines To Develop Tuberculosis Vaccine 244

GlaxoSmithKline Enters Into Co-Development Agreement With University of Cambridge 245

PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 246

Daiichi Sankyo And GlaxoSmithKline Form Joint Venture In Japan 247

Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 248

Desitin Arzneimittel Enters Into Co-Promotion Agreement With GlaxoSmithKline For Elontril 249

GlaxoSmithKline Enters Into Co-Development Agreement With Yale University 250

Five Prime Therapeutics Amends Agreement With GlaxoSmithKline 251

Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 252

GlaxoSmithKline Enters Into Co-Development Agreement With University of Dundee 253

Angiochem Enters Into Co-Development Agreement With GlaxoSmithKline 254

GlaxoSmithKline Enters Into Agreement With Coland Holdings 255

GlaxoSmithKline Enters Into Co-Development Agreement With Sienna Biotec 256

Eddingpharm Enters Distribution Agreement With GlaxoSmithKline For Relafen 257

Boston Pharma Enters into Licensing Agreement with GlaxoSmithKline 258

GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 259

Zai Lab Enters into Licensing agreement with GlaxoSmithKline 260

GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 261

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 262

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 263

Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 264

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 265

GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 266

Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 267

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 268

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 269

Codexis Enters into Licensing Agreement with GlaxoSmithKline for CodeEvolver Protein Engineering Platform 270

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 272

GlaxoSmithKline Enters into Licensing Agreement with Adaptimmune Therapeutics 273

GlaxoSmithKline Exercises Licensing Agreement with Adaptimmune 274

GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 276

GlaxoSmithKline Enters Into Licensing Agreement With Adimab 277

Immunocore Enters Into Licensing Agreement With GSK For ImmTACs 278

MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 279

GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 281

GlaxoSmithKline Enters Into Licensing Agreement With University of Texas MD Anderson Cancer Center For Antibodies 282

NeRRe Therapeutics Receives Neurokinin Receptor Antagonists from GlaxoSmithKline 283

Basilea Pharmaceutical Amends Terms of Licensing Agreement with Stiefel Labs for Toctino 284

Liquidia Technologies Exercises Option for Licensing Agreement with GlaxoSmithKline 286

GlaxoSmithKline Enters into Licensing Agreement with Pelago Bioscience for CETSA 287

Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 288

Medicines Patent Pool Extends Licensing Agreement with ViiV Healthcare 289

ViiV Healthcare Enters Into Licensing Agreement With Medicines Patent Pool For Epzicom 290

GlaxoSmithKline Enters Into Licensing Agreement With Alacris Theranostics For ModCell System 291

ViiV Healthcare Announces Licensing Agreement For Celsentri 292

GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 293

GlaxoSmithKline Plc, Key Competitors 394

GlaxoSmithKline Plc, Key Employees 395

GlaxoSmithKline Plc, Other Locations 396

GlaxoSmithKline Plc, Subsidiaries 396

GlaxoSmithKline Plc, Joint Venture 409

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

GlaxoSmithKline Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK's vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc (GSK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 11

List of Figures 16

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 18

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 20

GlaxoSmithKline Plc, Medical Devices Deals, 2012 to YTD 2018 22

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 23

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deal Details 46

Asset Purchase 46

ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 46

ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 48

GlaxoSmithKline Acquires Consumer Healthcare Pharma Business of Novartis 49

GlaxoSmithKline Acquires Vaccines Business of Novartis for up to USD7.1 Billion 51

Novartis India to Sell Its OTC Division to GlaxoSmithKline Consumer 53

ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 54

Stiefel Labs Acquires WBI-1001 From Welichem Biotech For USD 34 Million 55

Venture Financing 57

Gotham Therapeutics Raises USD54 Million in Series A Financing 57

Sitryx Therapeutics Raises USD30 Million in Series A Financing 59

Morphic Therapeutic Raises USD80 Million in Series B Financing 61

Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 63

Nimbus Therapeutics Raises USD65 Million in Financing 65

Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 67

Constellation Pharma Raises USD100 Million in Financing 69

Macrolide Pharma Raises USD20 Million in Venture Financing 71

Pandion Therapeutics Raises USD58 Million in Series A Finanicng 72

Atox Bio Raises USD30 Million in Financing 73

Palleon Pharma Raises USD47.6 Million in Series A Financing 75

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 76

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 78

TP Therapeutics Raises USD45 Million in Series C Financing 80

Pulmocide Raises USD30.4 Million in Series B Financing 81

Spero Therapeutics Raises USD51.7 Million in Series C Financing 83

Tioma Therapeutics Raises USD86 Million in Series A Financing 85

Second Genome Raises USD8.4 Million in Extended Series B Financing 86

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 87

PDI Therapeutics to Raise up to USD10 Million in Series A Venture Financing 89

Spero Therapeutics Raises USD30 Million in Series B Funding 90

Mission Therapeutics Raises USD85.7 Million in Financing Round 92

Nkarta Raises Funds through Venture Financing 94

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 95

Navitor Pharma Raises USD33 Million in Series B Financing 97

Constellation Pharma Raises USD55 Million Financing 99

True North Therapeutics Raises USD40 Million in Series C Financing 101

Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 103

Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 104

Atreca Raises USD56 Million in Series A Financing 105

Puridify Raises USD3.4 Million in Series A Financing 107

Decibel Therapeutics Raises USD52 Million in Series A Financing Round 108

Asceneuron Raises USD30.6 Million in Series A Financing 109

Gladius Pharma Raises USD3.3 Million in Series A Financing 111

Atopix Therapeutics Raises Additional Funds through Venture Financing 112

Adrenergics Raises up to USD10 Million in Series A Financing 113

CadheRx Therapeutics Raises up to USD10 Million in Series A Financing 114

Calporta Therapeutics Raises up to USD10 Million in Series A Financing 115

Spero Therapeutics Raises USD30 Million in Extended Series A Financing 116

PsiOxus Therapeutics Raises USD39.2 Million in Series C Financing 118

CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 120

CRISPR Therapeutics Raises USD29 Million in Series B Financing 122

ZappRx Raises USD5.6 Million in Series A Financing 124

Thrasos Therapeutics Raises USD21 Million in Series D Financing 125

Nimbus Therapeutics Raises USD43 Million in Series B Financing 127

Macrolide Pharma Raises USD22 Million in Series A Financing 129

Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 130

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 132

Atopix Therapeutics Raises Funds through Extended Series A Financing 134

Silarus Therapeutics to Raise up to USD10 Million in Series A Venture Financing 135

Thyritope Biosciences to Raise up to USD10 Million in Series A Venture Financing 136

Atox Bio Raises up to USD23 Million in Series E Venture Financing 137

Navitor Pharma Raises USD24 Million in Series A Financing 138

True North Therapeutics Raises USD22 Million in Series A Venture Financing 140

Puridify Raises USD1.43 Million in Seed Funding 142

Principia Biopharma Raises USD 50 Million In Series B Venture Financing 143

Spero Therapeutics Raises USD3 Million in Series A Venture Financing 145

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 146

RuiYi Raises USD 15 Million In Series B Financing 147

HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 149

VHsquared Secures Series A Funding Round 150

Sitari Pharma Raises USD 10 Million In Series A Financing 151

Mission Therapeutics Raises USD 32 Million In Series B Financing 152

Aileron Therapeutics Raises USD 30 Million In Series E Financing 154

F-Star Alpha Raises USD 13 Million In Series A Financing 156

iPierian Raises USD 30 Million In Series A Venture Financing 158

Effector Therapeutics Raises USD 45 Million In Series A Financing 160

Progenitor Labs Raises USD 5.8 Million In Seed Financing 162

Aileron Raises USD 12 Million In Extended Series D Financing 163

NeRRe Therapeutics Raises USD 18 Million In Series A Financing 165

River Vision Development Raises USD 17 Million In Series A Financing 166

Bicycle Therapeutics Raises USD 6 Million In Venture Financing 167

Applied Genetic Technologies Raises USD 37.5 Million In Series B Financing 169

HTG Molecular Diagnostics Raises USD 7.5 Million In Series E Financing 171

Thrasos Therapeutics Raises USD 35 Million In Venture Financing 172

SR One Plans To Invest In Biotechnology Company 174

Genocea Biosciences Raises USD 30 Million In Series C Financing 175

Principia Biopharma Raises Additional USD 13 Million In Series A Financing 177

PsiOxus Therapeutics Raises Additional USD 34 Million In Series B Financing 179

RaNA Therapeutics Raises Additional USD 18 Million In Series A Financing 181

Partnerships 183

GlaxoSmithKline and 23andMe Enter into Collaboration Agreement 183

MolMed Enters into Development Agreement with GlaxoSmithKline 185

Cloud Pharma Enters into Partnership with GlaxoSmithKline 186

Kymera Therapeutics Enters into Agreement with GlaxoSmithKline 187

National Institute for Health Research Enters into Research Agreement with GlaxoSmithKline 188

Owlstone Medical Enters into Co-Development Agreement with GlaxoSmithKline 189

Plasticell Enters into Agreement with GlaxoSmithKline 190

AbCellera Biologics Enters into Research Partnership with GlaxosmithKline 191

Oklahoma Medical Research Foundation Enters into Agreement with GlaxoSmithKline 192

Exscientia Enters into Partnership with GlaxoSmithKline (GSK) 193

Aseptic Technologies Enters into Agreement with MedCision 194

Warp Drive Bio Enters to Agreement with GlaxoSmithKline 195

Telo Therapeutics Enters into Research Agreement with GlaxoSmithKline 196

GlaxoSmithKline Biologicals Enters into Option Agreement with Aridis Pharma 197

Puridify Enters into Agreement with GlaxoSmithKline 198

Fimbrion Therapeutics Enters into Co-Development Agreement with GlaxoSmithKline 199

GlaxoSmithKline Enters into Co-Development Agreement with University of Leicester 200

GlaxoSmithKline Forms Joint Venture with Avalon Ventures 201

GlaxoSmithKline Enters into Agreement with Miltenyi Biotec 202

VBI Vaccines Enters into Research Agreement with GlaxoSmithKline Biologicals 203

Valneva Enters into R&D Agreement with GlaxoSmithKline 204

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 205

GlaxoSmithKline Enters into Research Agreement with NIAID 206

GlaxoSmithKline Forms Iron Horse Therapeutics with Avalon Ventures 207

GlaxoSmithKline Partners with Merck 208

Pfizer Enters into Agreement with GlaxoSmithKline 209

UC San Francisco Enters into Research Agreement with GlaxoSmithKline 210

MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 211

GlaxoSmithKline Enters into Partnership with Francis Crick Institute 212

University of North Carolina Forms Joint Venture with GlaxoSmithKline 213

Cold Spring Harbor Labs Enters into Co-Development Agreement with GlaxoSmithKline 214

MolMed Enters into Agreement with GlaxoSmithKline 215

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 216

GlaxoSmithKline, Monash University, McCall MacBain Foundation, Grand Challenges Canada and Planet Wheeler Foundation Enter into Co-Development Agreement 218

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 219

Bioversys Enters into Agreement with GlaxoSmithKline and University of Lille 220

Metabolon Enters Into Agreement With GlaxoSmithKline For Metabolomic Profiling Services 221

GlaxoSmithKline Enters Into Agreement With University of Texas MD Anderson Cancer Center For Immunotherapy Drugs 222

BioRap Enters into Agreement with GlaxoSmithKline 223

GlaxoSmithKline Enters into Partnership with Yale University 224

Santaris Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For RNA-Targeted Medicines 225

GlaxoSmithKline Forms Joint Venture With Biological E 226

ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 227

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 228

GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 229

GlaxoSmithKline Expands its Partnership with Adimab 230

GlaxoSmithKline Plans To Partner With Chinese Companies 231

GlaxoSmithKline Enters Into Co-Development Agreement With Institute of Chemical Engineering And Sciences 232

Eddingpharm Enters Into Distribution Agreement With GlaxoSmithKline For Tykerb 233

AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 234

Proteologics And GlaxoSmithKline Extend Their Research Agreement 235

Hospital for Sick Children Enters Into Research Agreement With GlaxoSmithKline To Discover Treatment For Cystic Fibrosis 236

Vanderbilt University Enters Into Research Agreement With GlaxoSmithKline For Obesity Drug 237

Priaxon Enters Into Co-Development Agreement With GlaxoSmithKline For Small Molecule Modulators Of PPIs 238

Chroma Therapeutics Expands Co-Development Agreement With GlaxoSmithKline 239

GlycoVaxyn Enters Into Co-Development Agreement With GlaxoSmithKline For Bacterial Vaccines 240

Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 241

GlaxoSmithKline Enters Into Agreement With Imagine Institute To Discover New Drugs For Netherton Syndrome 242

Chiromics Enters Into Drug Discovery Agreement With GlaxoSmithKline 243

Aeras Enters Into R&D Agreement With GlaxoSmithKline Vaccines To Develop Tuberculosis Vaccine 244

GlaxoSmithKline Enters Into Co-Development Agreement With University of Cambridge 245

PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 246

Daiichi Sankyo And GlaxoSmithKline Form Joint Venture In Japan 247

Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 248

Desitin Arzneimittel Enters Into Co-Promotion Agreement With GlaxoSmithKline For Elontril 249

GlaxoSmithKline Enters Into Co-Development Agreement With Yale University 250

Five Prime Therapeutics Amends Agreement With GlaxoSmithKline 251

Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 252

GlaxoSmithKline Enters Into Co-Development Agreement With University of Dundee 253

Angiochem Enters Into Co-Development Agreement With GlaxoSmithKline 254

GlaxoSmithKline Enters Into Agreement With Coland Holdings 255

GlaxoSmithKline Enters Into Co-Development Agreement With Sienna Biotec 256

Eddingpharm Enters Distribution Agreement With GlaxoSmithKline For Relafen 257

Licensing Agreements 258

Boston Pharma Enters into Licensing Agreement with GlaxoSmithKline 258

GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 259

Zai Lab Enters into Licensing agreement with GlaxoSmithKline 260

GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 261

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 262

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 263

Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 264

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 265

GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 266

Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 267

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 268

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 269

Codexis Enters into Licensing Agreement with GlaxoSmithKline for CodeEvolver Protein Engineering Platform 270

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 272

GlaxoSmithKline Enters into Licensing Agreement with Adaptimmune Therapeutics 273

GlaxoSmithKline Exercises Licensing Agreement with Adaptimmune 274

GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 276

GlaxoSmithKline Enters Into Licensing Agreement With Adimab 277

Immunocore Enters Into Licensing Agreement With GSK For ImmTACs 278

MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 279

GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 281

GlaxoSmithKline Enters Into Licensing Agreement With University of Texas MD Anderson Cancer Center For Antibodies 282

NeRRe Therapeutics Receives Neurokinin Receptor Antagonists from GlaxoSmithKline 283

Basilea Pharmaceutical Amends Terms of Licensing Agreement with Stiefel Labs for Toctino 284

Liquidia Technologies Exercises Option for Licensing Agreement with GlaxoSmithKline 286

GlaxoSmithKline Enters into Licensing Agreement with Pelago Bioscience for CETSA 287

Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 288

Medicines Patent Pool Extends Licensing Agreement with ViiV Healthcare 289

ViiV Healthcare Enters Into Licensing Agreement With Medicines Patent Pool For Epzicom 290

GlaxoSmithKline Enters Into Licensing Agreement With Alacris Theranostics For ModCell System 291

ViiV Healthcare Announces Licensing Agreement For Celsentri 292

GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 293

Equity Offering 294

Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 294

Theravance Biopharma Raises USD23 Million in Private Placement of Shares 296

Amicus Therapeutics Completes Private Placement Of Securities For USD 15 Million 297

GlaxoSmithKline Plc - Key Competitors 394

GlaxoSmithKline Plc - Key Employees 395

GlaxoSmithKline Plc - Locations And Subsidiaries 396

Head Office 396

Other Locations & Subsidiaries 396

Joint Venture 409

Recent Developments 410

Financial Announcements 410

Jul 25, 2018: GSK delivers improvements in sales, margins and cash flow in Q2 2018 410

Feb 07, 2018: GSK delivers improvements in sales, margins and cash flow in 2017 413

Oct 25, 2017: GSK delivers Q3 sales of 7.8 billion, +4% AER, +2% CER 414

Jul 26, 2017: GSK delivers further progress in Q2 and sets out new priorities for the Group 426

Apr 26, 2017: GSK delivers another quarter of continued progress 432

Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 435

Corporate Communications 451

Aug 07, 2018: Iain Mackay appointed GSK Chief Financial Officer 451

Jun 12, 2018: GSK announces changes to Vaccines and Global Manufacturing & Supply leadership 452

May 09, 2018: Simon Dingemans, Chief Financial Officer, to retire from GSK 453

Apr 18, 2018: GlaxoSmithKline Names Kevin Sin as new Senior Vice President and Head of Worldwide Business Development for Research & Development 454

Jan 09, 2018: Representative Director and President of GlaxoSmithKline Corporation Personnel notice 455

Nov 08, 2017: Patrick Vallance, President, R&D, GSK to become UK Government's Chief Scientific Adviser 456

Nov 08, 2017: Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK 457

Jul 25, 2017: Karenann Terrell appointed Chief Digital & Technology Officer, GSK 458

Jul 21, 2017: GSK announces Board and Committee changes 459

Jun 19, 2017: GSK confirms start date for Luke Miels 460

Jun 05, 2017: Four innovations to tackle under-five deaths win USD 1 million Healthcare Innovation Award from GSK and Save the Children 461

Apr 04, 2017: GSK responds to Cyclone Debbie 463

Jan 20, 2017: Luke Miels will succeed Abbas Hussain as President, Global Pharmaceuticals, GSK 464

Jan 19, 2017: Abbas Hussain to leave GSK 465

Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 466

Legal and Regulatory 467

Appendix 514

Methodology 514

About GlobalData 514

Contact Us 514

Disclaimer 514


List Of Figure

List of Figures

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 18

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 20

GlaxoSmithKline Plc, Medical Devices Deals, 2012 to YTD 2018 22


List Of Table

List of Tables

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 17

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 18

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 19

GlaxoSmithKline Plc, Deals By Therapy Area, 2012 to YTD 2018 20

GlaxoSmithKline Plc, Medical Devices Deals, 2012 to YTD 2018 22

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 23

ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 46

ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 48

GlaxoSmithKline Acquires Consumer Healthcare Pharma Business of Novartis 49

GlaxoSmithKline Acquires Vaccines Business of Novartis for up to USD7.1 Billion 51

Novartis India to Sell Its OTC Division to GlaxoSmithKline Consumer 53

ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 54

Stiefel Labs Acquires WBI-1001 From Welichem Biotech For USD 34 Million 55

Gotham Therapeutics Raises USD54 Million in Series A Financing 57

Sitryx Therapeutics Raises USD30 Million in Series A Financing 59

Morphic Therapeutic Raises USD80 Million in Series B Financing 61

Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 63

Nimbus Therapeutics Raises USD65 Million in Financing 65

Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 67

Constellation Pharma Raises USD100 Million in Financing 69

Macrolide Pharma Raises USD20 Million in Venture Financing 71

Pandion Therapeutics Raises USD58 Million in Series A Finanicng 72

Atox Bio Raises USD30 Million in Financing 73

Palleon Pharma Raises USD47.6 Million in Series A Financing 75

eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 76

Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 78

TP Therapeutics Raises USD45 Million in Series C Financing 80

Pulmocide Raises USD30.4 Million in Series B Financing 81

Spero Therapeutics Raises USD51.7 Million in Series C Financing 83

Tioma Therapeutics Raises USD86 Million in Series A Financing 85

Second Genome Raises USD8.4 Million in Extended Series B Financing 86

Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 87

PDI Therapeutics to Raise up to USD10 Million in Series A Venture Financing 89

Spero Therapeutics Raises USD30 Million in Series B Funding 90

Mission Therapeutics Raises USD85.7 Million in Financing Round 92

Nkarta Raises Funds through Venture Financing 94

Effector Therapeutics Raises USD40 Million in Series B Venture Financing 95

Navitor Pharma Raises USD33 Million in Series B Financing 97

Constellation Pharma Raises USD55 Million Financing 99

True North Therapeutics Raises USD40 Million in Series C Financing 101

Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 103

Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 104

Atreca Raises USD56 Million in Series A Financing 105

Puridify Raises USD3.4 Million in Series A Financing 107

Decibel Therapeutics Raises USD52 Million in Series A Financing Round 108

Asceneuron Raises USD30.6 Million in Series A Financing 109

Gladius Pharma Raises USD3.3 Million in Series A Financing 111

Atopix Therapeutics Raises Additional Funds through Venture Financing 112

Adrenergics Raises up to USD10 Million in Series A Financing 113

CadheRx Therapeutics Raises up to USD10 Million in Series A Financing 114

Calporta Therapeutics Raises up to USD10 Million in Series A Financing 115

Spero Therapeutics Raises USD30 Million in Extended Series A Financing 116

PsiOxus Therapeutics Raises USD39.2 Million in Series C Financing 118

CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 120

CRISPR Therapeutics Raises USD29 Million in Series B Financing 122

ZappRx Raises USD5.6 Million in Series A Financing 124

Thrasos Therapeutics Raises USD21 Million in Series D Financing 125

Nimbus Therapeutics Raises USD43 Million in Series B Financing 127

Macrolide Pharma Raises USD22 Million in Series A Financing 129

Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 130

Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 132

Atopix Therapeutics Raises Funds through Extended Series A Financing 134

Silarus Therapeutics to Raise up to USD10 Million in Series A Venture Financing 135

Thyritope Biosciences to Raise up to USD10 Million in Series A Venture Financing 136

Atox Bio Raises up to USD23 Million in Series E Venture Financing 137

Navitor Pharma Raises USD24 Million in Series A Financing 138

True North Therapeutics Raises USD22 Million in Series A Venture Financing 140

Puridify Raises USD1.43 Million in Seed Funding 142

Principia Biopharma Raises USD 50 Million In Series B Venture Financing 143

Spero Therapeutics Raises USD3 Million in Series A Venture Financing 145

Alios BioPharma Raises USD 41 Million In Series B Venture Financing 146

RuiYi Raises USD 15 Million In Series B Financing 147

HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 149

VHsquared Secures Series A Funding Round 150

Sitari Pharma Raises USD 10 Million In Series A Financing 151

Mission Therapeutics Raises USD 32 Million In Series B Financing 152

Aileron Therapeutics Raises USD 30 Million In Series E Financing 154

F-Star Alpha Raises USD 13 Million In Series A Financing 156

iPierian Raises USD 30 Million In Series A Venture Financing 158

Effector Therapeutics Raises USD 45 Million In Series A Financing 160

Progenitor Labs Raises USD 5.8 Million In Seed Financing 162

Aileron Raises USD 12 Million In Extended Series D Financing 163

NeRRe Therapeutics Raises USD 18 Million In Series A Financing 165

River Vision Development Raises USD 17 Million In Series A Financing 166

Bicycle Therapeutics Raises USD 6 Million In Venture Financing 167

Applied Genetic Technologies Raises USD 37.5 Million In Series B Financing 169

HTG Molecular Diagnostics Raises USD 7.5 Million In Series E Financing 171

Thrasos Therapeutics Raises USD 35 Million In Venture Financing 172

SR One Plans To Invest In Biotechnology Company 174

Genocea Biosciences Raises USD 30 Million In Series C Financing 175

Principia Biopharma Raises Additional USD 13 Million In Series A Financing 177

PsiOxus Therapeutics Raises Additional USD 34 Million In Series B Financing 179

RaNA Therapeutics Raises Additional USD 18 Million In Series A Financing 181

GlaxoSmithKline and 23andMe Enter into Collaboration Agreement 183

MolMed Enters into Development Agreement with GlaxoSmithKline 185

Cloud Pharma Enters into Partnership with GlaxoSmithKline 186

Kymera Therapeutics Enters into Agreement with GlaxoSmithKline 187

National Institute for Health Research Enters into Research Agreement with GlaxoSmithKline 188

Owlstone Medical Enters into Co-Development Agreement with GlaxoSmithKline 189

Plasticell Enters into Agreement with GlaxoSmithKline 190

AbCellera Biologics Enters into Research Partnership with GlaxosmithKline 191

Oklahoma Medical Research Foundation Enters into Agreement with GlaxoSmithKline 192

Exscientia Enters into Partnership with GlaxoSmithKline (GSK) 193

Aseptic Technologies Enters into Agreement with MedCision 194

Warp Drive Bio Enters to Agreement with GlaxoSmithKline 195

Telo Therapeutics Enters into Research Agreement with GlaxoSmithKline 196

GlaxoSmithKline Biologicals Enters into Option Agreement with Aridis Pharma 197

Puridify Enters into Agreement with GlaxoSmithKline 198

Fimbrion Therapeutics Enters into Co-Development Agreement with GlaxoSmithKline 199

GlaxoSmithKline Enters into Co-Development Agreement with University of Leicester 200

GlaxoSmithKline Forms Joint Venture with Avalon Ventures 201

GlaxoSmithKline Enters into Agreement with Miltenyi Biotec 202

VBI Vaccines Enters into Research Agreement with GlaxoSmithKline Biologicals 203

Valneva Enters into R&D Agreement with GlaxoSmithKline 204

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 205

GlaxoSmithKline Enters into Research Agreement with NIAID 206

GlaxoSmithKline Forms Iron Horse Therapeutics with Avalon Ventures 207

GlaxoSmithKline Partners with Merck 208

Pfizer Enters into Agreement with GlaxoSmithKline 209

UC San Francisco Enters into Research Agreement with GlaxoSmithKline 210

MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 211

GlaxoSmithKline Enters into Partnership with Francis Crick Institute 212

University of North Carolina Forms Joint Venture with GlaxoSmithKline 213

Cold Spring Harbor Labs Enters into Co-Development Agreement with GlaxoSmithKline 214

MolMed Enters into Agreement with GlaxoSmithKline 215

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 216

GlaxoSmithKline, Monash University, McCall MacBain Foundation, Grand Challenges Canada and Planet Wheeler Foundation Enter into Co-Development Agreement 218

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 219

Bioversys Enters into Agreement with GlaxoSmithKline and University of Lille 220

Metabolon Enters Into Agreement With GlaxoSmithKline For Metabolomic Profiling Services 221

GlaxoSmithKline Enters Into Agreement With University of Texas MD Anderson Cancer Center For Immunotherapy Drugs 222

BioRap Enters into Agreement with GlaxoSmithKline 223

GlaxoSmithKline Enters into Partnership with Yale University 224

Santaris Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For RNA-Targeted Medicines 225

GlaxoSmithKline Forms Joint Venture With Biological E 226

ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 227

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 228

GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 229

GlaxoSmithKline Expands its Partnership with Adimab 230

GlaxoSmithKline Plans To Partner With Chinese Companies 231

GlaxoSmithKline Enters Into Co-Development Agreement With Institute of Chemical Engineering And Sciences 232

Eddingpharm Enters Into Distribution Agreement With GlaxoSmithKline For Tykerb 233

AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 234

Proteologics And GlaxoSmithKline Extend Their Research Agreement 235

Hospital for Sick Children Enters Into Research Agreement With GlaxoSmithKline To Discover Treatment For Cystic Fibrosis 236

Vanderbilt University Enters Into Research Agreement With GlaxoSmithKline For Obesity Drug 237

Priaxon Enters Into Co-Development Agreement With GlaxoSmithKline For Small Molecule Modulators Of PPIs 238

Chroma Therapeutics Expands Co-Development Agreement With GlaxoSmithKline 239

GlycoVaxyn Enters Into Co-Development Agreement With GlaxoSmithKline For Bacterial Vaccines 240

Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 241

GlaxoSmithKline Enters Into Agreement With Imagine Institute To Discover New Drugs For Netherton Syndrome 242

Chiromics Enters Into Drug Discovery Agreement With GlaxoSmithKline 243

Aeras Enters Into R&D Agreement With GlaxoSmithKline Vaccines To Develop Tuberculosis Vaccine 244

GlaxoSmithKline Enters Into Co-Development Agreement With University of Cambridge 245

PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 246

Daiichi Sankyo And GlaxoSmithKline Form Joint Venture In Japan 247

Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 248

Desitin Arzneimittel Enters Into Co-Promotion Agreement With GlaxoSmithKline For Elontril 249

GlaxoSmithKline Enters Into Co-Development Agreement With Yale University 250

Five Prime Therapeutics Amends Agreement With GlaxoSmithKline 251

Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 252

GlaxoSmithKline Enters Into Co-Development Agreement With University of Dundee 253

Angiochem Enters Into Co-Development Agreement With GlaxoSmithKline 254

GlaxoSmithKline Enters Into Agreement With Coland Holdings 255

GlaxoSmithKline Enters Into Co-Development Agreement With Sienna Biotec 256

Eddingpharm Enters Distribution Agreement With GlaxoSmithKline For Relafen 257

Boston Pharma Enters into Licensing Agreement with GlaxoSmithKline 258

GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 259

Zai Lab Enters into Licensing agreement with GlaxoSmithKline 260

GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 261

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 262

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 263

Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 264

Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 265

GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 266

Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 267

GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 268

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 269

Codexis Enters into Licensing Agreement with GlaxoSmithKline for CodeEvolver Protein Engineering Platform 270

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 272

GlaxoSmithKline Enters into Licensing Agreement with Adaptimmune Therapeutics 273

GlaxoSmithKline Exercises Licensing Agreement with Adaptimmune 274

GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 276

GlaxoSmithKline Enters Into Licensing Agreement With Adimab 277

Immunocore Enters Into Licensing Agreement With GSK For ImmTACs 278

MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 279

GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 281

GlaxoSmithKline Enters Into Licensing Agreement With University of Texas MD Anderson Cancer Center For Antibodies 282

NeRRe Therapeutics Receives Neurokinin Receptor Antagonists from GlaxoSmithKline 283

Basilea Pharmaceutical Amends Terms of Licensing Agreement with Stiefel Labs for Toctino 284

Liquidia Technologies Exercises Option for Licensing Agreement with GlaxoSmithKline 286

GlaxoSmithKline Enters into Licensing Agreement with Pelago Bioscience for CETSA 287

Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 288

Medicines Patent Pool Extends Licensing Agreement with ViiV Healthcare 289

ViiV Healthcare Enters Into Licensing Agreement With Medicines Patent Pool For Epzicom 290

GlaxoSmithKline Enters Into Licensing Agreement With Alacris Theranostics For ModCell System 291

ViiV Healthcare Announces Licensing Agreement For Celsentri 292

GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 293

GlaxoSmithKline Plc, Key Competitors 394

GlaxoSmithKline Plc, Key Employees 395

GlaxoSmithKline Plc, Other Locations 396

GlaxoSmithKline Plc, Subsidiaries 396

GlaxoSmithKline Plc, Joint Venture 409

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

GlaxoSmithKline Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.